Cubist Systematic Strategies’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-58,993
| Closed | -$1.19M | – | 3748 |
|
|
2021
Q3 | $1.19M | Buy |
58,993
+44,923
| +319% | +$1.24M | 0.02% | 1383 |
|
|
2021
Q2 | $525K | Sell |
14,070
-17,075
| -55% | -$523K | 0.01% | 1980 |
|
|
2021
Q1 | $796K | Sell |
31,145
-16,080
| -34% | -$411K | 0.01% | 1676 |
|
|
2020
Q4 | $1.04M | Buy |
+47,225
| New | +$1.04M | 0.01% | 1358 |
|
|
2020
Q3 | – | Sell |
-10,361
| Closed | -$263K | – | 2712 |
|
|
2020
Q2 | $263K | Buy |
10,361
+6,632
| +178% | +$143K | ﹤0.01% | 1903 |
|
|
2020
Q1 | $69K | Sell |
3,729
-100,848
| -96% | -$1.96M | ﹤0.01% | 1970 |
|
|
2019
Q4 | $2.3M | Buy |
+104,577
| New | +$2.1M | 0.04% | 670 |
|
|
2019
Q3 | – | Sell |
-28,161
| Closed | -$444K | – | 2599 |
|
|
2019
Q2 | $444K | Buy |
28,161
+1,871
| +7% | +$25.4K | 0.01% | 1565 |
|
|
2019
Q1 | $385K | Buy |
26,290
+14,068
| +115% | +$162K | 0.01% | 1349 |
|
|
2018
Q4 | $131K | Buy |
12,222
+489
| +4% | +$6.43K | 0.01% | 1692 |
|
|
2018
Q3 | $179K | Buy |
+11,733
| New | +$171K | 0.01% | 1450 |
|
|
2018
Q2 | – | Sell |
-10,665
| Closed | -$102K | – | 2145 |
|
|
2018
Q1 | $102K | Buy |
+10,665
| New | +$115K | 0.01% | 1588 |
|
Other funds holding DRNA
Cubist Systematic Strategies's DRNA Position: Q4 2021 in Review
Cubist Systematic Strategies sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 58,993 shares — an estimated $1.19M sold.
Cubist Systematic Strategies first reported a position in DRNA in Q1 2018 and held it in 12 quarters. The position peaked at $2.3M in Q4 2019. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- Cubist Systematic Strategies reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- Cubist Systematic Strategies sold 58,993 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $1.19M.
- Cubist Systematic Strategies first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2018 and held it in 12 quarters.
- Cubist Systematic Strategies's Dicerna Pharmaceuticals, Inc. position peaked at $2.3M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on Cubist Systematic Strategies's 13F filing for Q4 2021, filed 14 Feb 2022.